Johanna Escher

Full professor

Erasmus University Rotterdam
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2026

Introduction Real-world data regarding subcutaneous infliximab (SC-IFX) in patients with pediatric inflammatory bowel disease IBD (PIBD) is scarce. We evaluated SC-IFX as maintenance therapy in PIBD patients who switched to SC-IFX from intravenous infliximab (IV-IFX) treatment. Methods In this retrospective multicenter study we identified PIBD patients who switched to SC-IFX. The primary outcome was treatment persistence at up to 12 months post-switch. Secondary outcomes included relapse rate (defined as Pediatric Ulcerative Colitis Activity Index [PUCAI] ≥10/ weighted PCDAI ≥ 12.5 with biochemical/endoscopic evidence of disease activity), IFX trough levels, immunogenicity, safety, and acceptance. Results Sixty-six patients switched to SC-IFX (48% males; median switch-age, 16.5 years; IQR, 14.9-17.3 years; median switch-weight, 60 kg; range, 13-102 kg), 41/66 (62%) with Crohn Disease. Pre-switch, the median IV-IFX maintenance dose was 10 mg/kg every 6 weeks; 58/66 patients (88%) were in clinical remission. The initial SC-IFX regimen was 120 mg every other week in 62/66 patients (94%). SC-IFX persistence was 78% (95% CI, 66-91) at 12 months post-switch, with 89% of patients persisting on IFX, either intravenous (IV) or subcutaneous (SC), at the end of follow-up. Relapses were observed in 11/66 patients (17%) over a median follow-up of 11.0 months (IQR, 5.1-12.0); 6 patients underwent SC-IFX dose intensification, with 3 successfully regaining clinical response. Regarding anti-drug antibodies (ADA), 3 out of 4 patients who were ADA positive on IV-IFX resolved post-switch. Overall, 19/66 patients (29%) reported 21 adverse events (AEs), including 3/21 severe AEs. The majority (53/66 patients; 80%) expressed a positive attitude toward SC-IFX. Conclusions The largest documented PIBD cohort switching to SC-IFX to date showed high treatment persistence at 1 year, confirming SC-IFX as an effective and safe maintenance alternative to IV-IFX.

Year:

2026

Access to quality healthcare for individuals with chronic diseases like inflammatory bowel disease (IBD) remains a global challenge. Tweens (aged 9-12 years) and teens (typically aged 13-19 years) with IBD face unique challenges compared to adults, including limited access to medications, difficulties transitioning to adult care, and barriers to clinical trial enrollment. Additional concerns include mental health, social media influence, and growth through puberty. This review article brings together current evidence reported by pediatric IBD clinicians worldwide to highlight these issues. While many challenges are universal, some are region specific and reflect geographic disparities in care.

Year:

2026

Year:

2026

Year:

2025

Objectives Living with inflammatory bowel disease (IBD) can have a significant impact on children. Many children with IBD experience symptoms of anxiety or depression. Routine screening for mental health has been recommended. This preregistered study aimed to describe the implementation of patient‐reported outcome measures (PROMs) in routine healthcare at an outpatient IBD clinic, as well as assess its feasibility. Methods Before every outpatient clinic appointment, PROMs were distributed to all patients aged 8 and older, as well as their parents. PROMs related to anxiety, depression, fatigue, pain and IBD‐related quality of life were selected by a paediatric gastroenterologist and psychologist, and integrated into electronic health records. Patients who completed PROMs on two occasions were invited to complete a user experience survey, focussing on their experiences with the PROMs. Results A total of 2910 questionnaires were distributed. Adherence was 44.7%, with 175 patients or parents completing at least one questionnaire. User experience results of 24 patients showed they were satisfied with both the patient portal and the discussion with the healthcare provider. Five patients perceived the length of the questionnaires as too long, or as having to complete the questionnaires too frequently. Outcomes of 114 patients with 187 sets of questionnaires, described in the supplement, showed that up to 82% reported pain and/or fatigue. About 20% of patients reported symptoms of anxiety and/or depression. Conclusions Implementation of PROMs is feasible, but the length and frequency of PROMs can be improved. Healthcare professionals wanting to work with PROMs should carefully decide which PROMs to select. Trial Identification This study was registered prospectively on the Open Science Framework (OSF), https://osf.io/ef8wm/?view_only=67b4d7e55f684364b8a338fb1898e841 .

Year:

2025

Background and Aims The effectiveness of transition programs from pediatric to adult healthcare in adolescents with inflammatory bowel disease (IBD) is not clear, as prospective studies using validated outcome measures for transition are lacking. This study aimed to develop and validate a quantitative Transition Success Score (TSS), and to apply it in a multicenter setting to assess the effectiveness of transitional care. Methods The Top 10 outcome items related to a successful transition, identified through an international Delphi study with IBD stakeholders, were integrated into a generic questionnaire, the TSS. In a prospective, multicenter study, the TSS was scored by adult healthcare providers, young adult patients, and caregivers, 9-15 months after transfer of care. Results In 7 Dutch hospitals, 160 patients completed the TSS. The mean score was 25 (range 17-27), 25.6% of patients achieving maximum score. Hypothesis testing for construct validity revealed significant associations with characteristics related to transitional care, such as knowledge, independence, and quality of life (p < 0.005). Structural validation indicated the score was most effective at discerning lower levels of transition success. Internal consistency was acceptable (0.64). High disease burden, exacerbation during or after transfer, and certain personality profiles were associated with lower scores. Conclusions The TSS serves as a quantitative tool to evaluate the effectiveness of transitional care interventions and to identify IBD patients at risk of encountering challenges during the transition to adult healthcare.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Nadeem Ahmad Afzal

Associate Professor (Hon)

University of Southampton

UNITED KINGDOM
View details

Richard Hansen

Clinical Reader in Child Health

University of Dundee

UNITED KINGDOM
View details

Eytan Wine

Division Head

Hospital for Sick Children

CANADA
View details

miranda van tilburg

Research Director

Marshall University

UNITED STATES
View details

John Vlot

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Patrick van Rheenen

Pediatric Gastroenterologist, Head IBD Unit

University Medical Center Groningen

NETHERLANDS
View details

Michiel van Wijk

Visiting Professor

Catholic University of Leuven

BELGIUM
View details

Subra Kugathasan

Professor

Emory University

UNITED STATES
View details

Saskia Vande Velde

Ghent University Hospital

BELGIUM
View details

AnneLoes van Staa

Professor / Lector

Erasmus University Rotterdam

NETHERLANDS
View details

Jane Sattoe

Associate Professor

The Hague University of Applied Sciences

NETHERLANDS
View details

Marten Poley

Erasmus University Rotterdam

NETHERLANDS
View details

Arta Aliu

University of Maastricht

NETHERLANDS
View details